Academic innovation project, part of SPARK Norway, with repositioning of a phosphodiesterase 2 (PDE2) inhibitor to prevent ventricular arrhythmias.
Ticker:
N/A
Exchange:
N/A
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Norway
Year Founded:
Not Provided
Main Therapeutic Focus:
Cardiovascular
Lead Product in Development:
Repositioning of PDE2 inhibitor
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
